In this Healio Video Perspective, Theodore Leng, MD, FACS, discusses the real-world use of faricimab for neovascular age-related macular degeneration.
The data, presented at the Retina Society meeting, are from the FARETINA and FARWIDE studies, which took place in the United States and the United Kingdom, respectively.
“The FARETINA and the FARWIDE real-world studies are the largest ongoing registry studies of faricimab, and additional analyses are planned as the data continues to grow and mature,” Leng said.